Perlman E - Search Results

1

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.

Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G, Perlman E, Anderson JR, Grundy P, Dome JS, Pritchard-Jones K. Maschietto M, et al. Among authors: perlman e. PLoS One. 2014 Oct 14;9(10):e109924. doi: 10.1371/journal.pone.0109924. eCollection 2014. PLoS One. 2014. PMID: 25313908 Free PMC article.

2

High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor.

Dome JS, Chung S, Bergemann T, Umbricht CB, Saji M, Carey LA, Grundy PE, Perlman EJ, Breslow NE, Sukumar S. Dome JS, et al. Among authors: perlman ej. Cancer Res. 1999 Sep 1;59(17):4301-7. Cancer Res. 1999. PMID: 10485476

3

Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group.

Green DM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Perlman E, Donaldson M, Grundy PE, Weetman R, Coppes MJ, Malogolowkin M, Shearer P, Coccia P, Kletzel M, Thomas PR, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D. Green DM, et al. Among authors: perlman e. J Clin Oncol. 2001 Sep 1;19(17):3719-24. doi: 10.1200/JCO.2001.19.17.3719. J Clin Oncol. 2001. PMID: 11533093 Clinical Trial.

4

Genetic and genetic expression analyses of clear cell sarcoma of the kidney.

Schuster AE, Schneider DT, Fritsch MK, Grundy P, Perlman EJ. Schuster AE, et al. Among authors: perlman ej. Lab Invest. 2003 Sep;83(9):1293-9. doi: 10.1097/01.lab.0000087850.69363.59. Lab Invest. 2003. PMID: 13679437 Free article.

5

Protocol for the examination of specimens from patients with Wilms tumor (nephroblastoma) or other renal tumors of childhood.

Qualman SJ, Bowen J, Amin MB, Srigley JR, Grundy PE, Perlman EJ; Members of the Cancer Committee, College of American Pathologists. Qualman SJ, et al. Among authors: perlman ej. Arch Pathol Lab Med. 2003 Oct;127(10):1280-9. doi: 10.5858/2003-127-1280-PFTEOS. Arch Pathol Lab Med. 2003. PMID: 14521468 Free article. No abstract available.

6

Management of Wilms' tumour: current practice and future goals.

Kalapurakal JA, Dome JS, Perlman EJ, Malogolowkin M, Haase GM, Grundy P, Coppes MJ. Kalapurakal JA, et al. Lancet Oncol. 2004 Jan;5(1):37-46. doi: 10.1016/s1470-2045(03)01322-6. Lancet Oncol. 2004. PMID: 14700607 Review.

7

Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group.

Kalapurakal JA, Nan B, Norkool P, Coppes M, Perlman E, Beckwith B, Ritchey M, Breslow N, Grundy P, D'angio GJ, Green DM, Thomas PR. Kalapurakal JA, et al. Among authors: perlman e. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1379-84. doi: 10.1016/j.ijrobp.2004.05.057. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590168

8

Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.

Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM; National Wilms Tumor Study Group. Grundy PE, et al. Among authors: perlman e. J Clin Oncol. 2005 Oct 10;23(29):7312-21. doi: 10.1200/JCO.2005.01.2799. Epub 2005 Aug 29. J Clin Oncol. 2005. PMID: 16129848 Clinical Trial.

9

High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor.

Dome JS, Bockhold CA, Li SM, Baker SD, Green DM, Perlman EJ, Hill DA, Breslow NE. Dome JS, et al. Among authors: perlman ej. J Clin Oncol. 2005 Dec 20;23(36):9138-45. doi: 10.1200/JCO.2005.00.562. Epub 2005 Sep 19. J Clin Oncol. 2005. PMID: 16172460

10

Current issues in Wilms tumor management.

Grundy P, Perlman E, Rosen NS, Warwick AB, Glade Bender J, Ehrlich P, Hoffer FA, Lee ND. Grundy P, et al. Among authors: perlman e. Curr Probl Cancer. 2005 Sep-Oct;29(5):221-60. doi: 10.1016/j.currproblcancer.2005.08.002. Curr Probl Cancer. 2005. PMID: 16216623 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

357 results

Search Page

Filters